Valneva SE (VALN) Profit After Tax (2021 - 2026)
Valneva SE (VALN) posted quarterly Profit After Tax of -$36.5 million for Q1 2026, down 447.41% year-on-year from $10.5 million in Q1 2025, and up 82.22% on a QoQ basis from -$205.3 million in Q4 2025.
Valneva SE (VALN) Profit After Tax (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Profit After Tax for 6 consecutive years, with -$36.5 million the latest figure, recorded in Q1 2026.
- Quarterly Profit After Tax fell 447.41% year-over-year to -$36.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$178.1 million (down 152.93% YoY) and the FY2025 annual result came in at -$131.1 million, down 840.64% from the prior year.
- Profit After Tax grew to -$36.5 million in Q1 2026 per VALN's latest filing, from -$205.3 million in the prior quarter.
- Over the last five years, Profit After Tax for VALN reached as high as $97.9 million in Q3 2025 and fell as low as -$224.8 million in Q2 2022.
- A 5-year average of -$27.1 million and a median of -$28.4 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2025 — Profit After Tax surged 1031.04% — and 2026, when it slumped 447.41%.
- Year by year, Profit After Tax stood at -$50.3 million in 2022, then increased by 27.25% to -$36.6 million in 2023, then dropped by 14.87% to -$42.0 million in 2024, then slumped by 388.29% to -$205.3 million in 2025, then soared by 82.22% to -$36.5 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$36.5 million, -$205.3 million, and $97.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -36.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.50 Mn |
| Dec 31, 2025 | -205.26 Mn |
| Sep 30, 2025 | 97.85 Mn |
| Jun 30, 2025 | -34.20 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | -42.04 Mn |
| Sep 30, 2024 | -10.51 Mn |
| Jun 30, 2024 | -28.37 Mn |
| Mar 31, 2024 | 67.04 Mn |
| Dec 31, 2023 | -36.59 Mn |
| Sep 30, 2023 | -118.71 Mn |
| Jun 30, 2023 | 19.25 Mn |
| Mar 31, 2023 | 20.63 Mn |
| Dec 31, 2022 | -50.30 Mn |
| Sep 30, 2022 | 82.41 Mn |
| Jun 30, 2022 | -224.78 Mn |
| Mar 31, 2022 | 29.63 Mn |
| Dec 31, 2021 | -363.41 Mn |
| Sep 30, 2021 | 181.54 Mn |
| Jun 30, 2021 | 66.79 Mn |